Literature DB >> 24892378

Corneal collagen cross-linking for Terrien marginal degeneration.

Farhad Hafezi, Zisis Gatzioufas, Theo G Seiler, Theo Seiler.   

Abstract

PURPOSE: To report the long-term clinical outcome of a patient diagnosed as having Terrien marginal degeneration (TMD) who was subjected to corneal collagen cross-linking (CXL) with ultraviolet-A and riboflavin in both eyes.
METHODS: Topographical changes were assessed by high-resolution Scheimpflug imaging and anterior segment optical coherence tomography. Eccentric epithelium-off CXL was performed in both eyes while protecting the corneal limbus. Irradiation was performed with a fluence of 5.4 J/cm(2), using 3 mW/cm(2) for 30 minutes.
RESULTS: Five years of postoperative follow-up showed regression of the keratometric values, a local thickening of the corneal stroma, and bilateral improvement of corrected distance visual acuity.
CONCLUSIONS: CXL may arrest progression in TMD and even reverse the catabolic process in the corneal stroma. CXL might represent an alternative therapeutic approach for the management of TMD. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24892378     DOI: 10.3928/1081597X-20140527-02

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  3 in total

1.  Spontaneous corneal perforation in Terrien's marginal degeneration in childhood: A case report.

Authors:  Junkyu Chung; Kyung Hyun Jin; Jaheon Kang; Tae Gi Kim
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 2.  Patient selection for corneal collagen cross-linking: an updated review.

Authors:  Virgilio Galvis; Alejandro Tello; Alvaro I Ortiz; Luis C Escaf
Journal:  Clin Ophthalmol       Date:  2017-04-07

3.  Globe rupture following eye rubbing in a case of Terrien's marginal degeneration in a young male.

Authors:  Surbhi Khurana; Parul Chawla Gupta; Aman Kumar; Jagat Ram
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.